Antihypertensive Drugs Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Antihypertensive Drugs Market 

5.1. COVID-19 Landscape: Antihypertensive Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Antihypertensive Drugs Market, By Drug Class

8.1. Antihypertensive Drugs Market Revenue and Volume Forecast, by Drug Class, 2024-2033

8.1.1. Diuretics

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. ACE Inhibitors

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Calcium Channel Blockers

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Beta-adrenergic Blockers

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. Vasodilators

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

8.1.6. Others

8.1.6.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Antihypertensive Drugs Market, By Type

9.1. Antihypertensive Drugs Market Revenue and Volume Forecast, by Type, 2024-2033

9.1.1. Primary Hypertension

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Secondary Hypertension

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Antihypertensive Drugs Market, By Route of Administration 

10.1. Antihypertensive Drugs Market Revenue and Volume Forecast, by Route of Administration, 2024-2033

10.1.1. Oral

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Injectables

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Others

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Antihypertensive Drugs Market, By Distribution Channel 

11.1. Antihypertensive Drugs Market Revenue and Volume Forecast, by Distribution Channel, 2024-2033

11.1.1. Retail Pharmacy

11.1.1.1. Market Revenue and Volume Forecast (2021-2033)

11.1.2. Hospital Pharmacy

11.1.2.1. Market Revenue and Volume Forecast (2021-2033)

11.1.3. Online Pharmacy

11.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 12. Global Antihypertensive Drugs Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.1.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.1.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.1.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.1.5.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.1.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.1.6.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.1.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.2.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.2.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.2.5.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.2.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.2.6.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.2.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.2.7.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.2.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.2.8.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.2.8.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.3.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.3.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.3.5.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.3.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.3.6.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.3.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.3.7.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.3.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.3.8.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.3.8.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.4.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.4.5.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.4.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.4.6.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.4.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.4.7.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.4.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.4.8.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.4.8.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.5.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.5.5.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.5.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2033)

12.5.6.2. Market Revenue and Volume Forecast, by Type (2021-2033)

12.5.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)

12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel (2021-2033)

Chapter 13. Company Profiles

13.1. Sun Pharmaceutical Industries Ltd.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Lupin

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Pfizer Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. AstraZeneca

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Merck & Co., Inc.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. DAIICHI SANKYO COMPANY, LIMITED

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Johnson & Johnson Services, Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Novartis AG

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Boehringer Ingelheim International GmbH

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Sanofi

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms